Peter McAllister
Yale University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter McAllister.
Headache | 2017
Stephen D. Silberstein; Paul Winner; Peter McAllister; Stewart J. Tepper; Rashmi Halker; Ramy Mahmoud; Joao Siffert
To further characterize the clinical utility of AVP‐825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP‐825 vs 100 mg oral sumatriptan (NCT01667679). AVP‐825 was approved in January 2016 by the US Food and Drug Administration under the name ONZETRA® Xsail® (sumatriptan nasal powder) for the acute treatment of migraine with or without aura in adults.
Neurology | 2017
Jean-Michel Gracies; Alberto Esquenazi; Allison Brashear; Marta Banach; Serdar Kocer; Robert Jech; Svetlana Khatkova; Ján Benetin; Michele Vecchio; Peter McAllister; Jan Ilkowski; Stanisław Ochudło; Anne Sophie Grandoulier; Claire Vilain; Philippe Picaut
Objective: To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for adults with chronic hemiparesis and assess long-term safety and efficacy of repeated injections. Methods: In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study followed by a 1-year open-label, multiple-cycle extension, adults ≥6 months after stroke/brain injury received one lower limb injection (abobotulinumtoxinA 1,000 U, abobotulinumtoxinA 1,500 U, placebo) followed by ≤4 open-label cycles (1,000, 1,500 U) at ≥12-week intervals. Efficacy measures included Modified Ashworth Scale (MAS) in gastrocnemius–soleus complex (GSC; double-blind primary endpoint), physician global assessment (PGA), and comfortable barefoot walking speed. Safety was the open-label primary endpoint. Results: After a single injection, mean (95% confidence interval) MAS GSC changes from baseline at week 4 (double-blind, n = 381) were as follows: −0.5 (−0.7 to −0.4) (placebo, n = 128), −0.6 (−0.8 to −0.5) (abobotulinumtoxinA 1,000 U, n = 125; p = 0.28 vs placebo), and −0.8 (−0.9 to −0.7) (abobotulinumtoxinA 1,500 U, n = 128; p = 0.009 vs placebo). Mean week 4 PGA scores were as follows: 0.7 (0.5, 0.9) (placebo), 0.9 (0.7, 1.1) (1,000 U; p = 0.067 vs placebo), and 0.9 (0.7, 1.1) (1,500 U; p = 0.067); walking speed was not significantly improved vs placebo. At cycle 4, week 4 (open-label), mean MAS GSC change reached −1.0. Incremental improvements in PGA and walking speed occurred across open-label cycles; by cycle 4, week 4, mean PGA was 1.9, and walking speed increased +25.3% (17.5, 33.2), with 16% of participants walking >0.8 m/s (associated with community mobility; 0% at baseline). Tolerability was good and consistent with the known abobotulinumtoxinA safety profile. Conclusions: In chronic hemiparesis, single abobotulinumtoxinA (Dysport Ipsen) administration reduced muscle tone. Repeated administration over a year was well-tolerated and improved walking speed and likelihood of achieving community ambulation. Clinicaltrial.gov identifiers: NCT01249404, NCT01251367. Classification of evidence: The double-blind phase of this study provides Class I evidence that for adults with chronic spastic hemiparesis, a single abobotulinumtoxinA injection reduces lower extremity muscle tone.
Cranio-the Journal of Craniomandibular Practice | 2015
Egilius L. H. Spierings; Peter McAllister; Tanya R. Bilchik
Abstract Aims: A review on headache and insomnia revealed that insomnia is a risk factor for increased headache frequency and headache intensity in migraineurs. The authors designed a randomized, double blind, placebo-controlled, parallel-group, pilot study in which migraineurs who also had insomnia were enrolled, to test this observation. Methodology: In the study, the authors treated 79 subjects with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia for 6 weeks with 3 mg eszopiclone (Lunesta®) or placebo at bedtime. The treatment was preceded by a 2-week baseline period and followed by a 2-week run-out period. Results: Of the 79 subjects treated, 75 were evaluable, 35 in the eszopiclone group, and 40 in the placebo group. At baseline, the groups were comparable except for sleep latency. Of the three remaining sleep variables, total sleep time, nighttime awakenings, and sleep quality, the number of nighttime awakenings during the 6-week treatment period was significantly lower in the eszopiclone group than in the placebo group (P = 0·03). Of the three daytime variables, alertness, fatigue, and functioning, this was also the case for fatigue (P = 005). The headache variables, frequency, duration, and intensity, did not show a difference from placebo during the 6-week treatment period. Conclusions: The study did not meet primary endpoint, that is, the difference in total sleep time during the 6-week treatment period between eszopiclone and placebo was less than 40 minutes. Therefore, it failed to answer the question as to whether insomnia is, indeed, a risk factor for increased headache frequency and headache intensity in migraineurs.
Pm&r | 2017
Christina M. Marciniak; Peter McAllister; Heather W. Walker; Allison Brashear; Steven R. Edgley; Thierry Deltombe; Svetlana Khatkova; Marta Banach; Fatma Gul; Claire Vilain; Philippe Picaut; Anne Sophie Grandoulier; Jean Michel Gracies
To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT‐A).
Pm&r | 2017
Peter McAllister; Svetlana Khatkova; Steven Faux; Philippe Picaut; Jovita Balcaitiene; Romain Raymond; Jean-Michel Gracies
(76%). In bivariate analysis, disposition was associated with initial NIHSS (P<.05) but not age, sex, or race. In multivariate analysis, only initial NIHSS was associated with disposition. Conclusions: Patients with a NIHSS>4 are more likely to be discharged to a rehabilitation facility. Early PM&R consultation for patients with a NIHSS score>4 may enable patients who are candidates for acute rehabilitation to enter rehabilitation at the most appropriate facility at the correct timing. Level of Evidence: Level III
Pm&r | 2015
Christina M. Marciniak; Allison Brashear; Peter McAllister; Bruce Rubin; Peter Hedera; Stuart Isaacson; Philippe Picaut; Jean-Michel Gracies
encephalopathy; typically, cefepime-induced neurotoxicity occurs within a week after initiation of the agent. Conclusion: As increasingly medically complex patients on multiple antibiotic regimens are cared for in the acute inpatient rehabilitation setting, physiatrists require a heightened awareness for potential adverse effects from medications. Cefepime-induced encephalopathy should be suspected in the presence of acute mental status changes, even if the treatment duration exceeds a week.
Polski Przegląd Neurologiczny | 2018
Jean-Michel Gracies; Alberto Esquenazi; Allison Brashear; Marta Banach; Serdar Kocer; Robert Jech; Svetlana Khatkova; Ján Benetin; Michele Vecchio; Peter McAllister; Jan Ilkowski; Stanisław Ochudło; Anne Sophie Grandoulier; Claire Vilain; Philippe Picaut
Neurology | 2018
Peter McAllister; Julio Pascual Gomez; Lora McGill; Lawrence Newman; Cristina Tassorelli; Feng Zhang; Hernan Picard; Daniel Mikol
Journal of Headache and Pain | 2018
Todd J. Schwedt; Uwe Reuter; Stewart J. Tepper; Messoud Ashina; David Kudrow; Gregor Broessner; Guy P. Boudreau; Peter McAllister; Thuy Vu; Feng Zhang; Sunfa Cheng; Hernan Picard; Shihua Wen; Joseph Kahn; Jan Klatt; Daniel Mikol
Annals of Physical and Rehabilitation Medicine | 2017
Serdar Kocer; Jean-Michel Gracies; Allison Brashear; Alberto Esquenazi; Robert Jech; Marta Banach; Peter McAllister; Anne-Sophie Grandoulier; Claire Vilain; Philippe Picaut